Pathophysiology and pharmacology of small intestinal motility

R. D. Rothstein, Ann Ouyang

Research output: Contribution to journalReview article

Abstract

Tremendous progress continues in the area of small bowel motility and pharmacology. Our understanding of small bowel motility has been further advanced over the past year with studies examining the role of various mediators of gastrointestinal physiology. Additional new evidence supports the role of nitric oxide as a key intracellular messenger for nonadrenergic, noncholinergic inhibition of the gastrointestinal tract. Our ability to more accurately define motor abnormalities of the small bowel has been expanded with new diagnostic techniques. There has also been greater delineation of the small bowel motility abnormalities that exist in a number of pathologic conditions. Our therapeutic options have increased as progress in pharmacologic therapy for small bowel dysmotility continues to be advanced.

Original languageEnglish (US)
Pages (from-to)156-162
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Gastrointestinal Motility
Pharmacology
Gastrointestinal Tract
Nitric Oxide
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{7ce07f9f774a4e72930e8896f5281e56,
title = "Pathophysiology and pharmacology of small intestinal motility",
abstract = "Tremendous progress continues in the area of small bowel motility and pharmacology. Our understanding of small bowel motility has been further advanced over the past year with studies examining the role of various mediators of gastrointestinal physiology. Additional new evidence supports the role of nitric oxide as a key intracellular messenger for nonadrenergic, noncholinergic inhibition of the gastrointestinal tract. Our ability to more accurately define motor abnormalities of the small bowel has been expanded with new diagnostic techniques. There has also been greater delineation of the small bowel motility abnormalities that exist in a number of pathologic conditions. Our therapeutic options have increased as progress in pharmacologic therapy for small bowel dysmotility continues to be advanced.",
author = "Rothstein, {R. D.} and Ann Ouyang",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00001574-199403000-00008",
language = "English (US)",
volume = "10",
pages = "156--162",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Pathophysiology and pharmacology of small intestinal motility. / Rothstein, R. D.; Ouyang, Ann.

In: Current Opinion in Gastroenterology, Vol. 10, No. 2, 01.01.1994, p. 156-162.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pathophysiology and pharmacology of small intestinal motility

AU - Rothstein, R. D.

AU - Ouyang, Ann

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Tremendous progress continues in the area of small bowel motility and pharmacology. Our understanding of small bowel motility has been further advanced over the past year with studies examining the role of various mediators of gastrointestinal physiology. Additional new evidence supports the role of nitric oxide as a key intracellular messenger for nonadrenergic, noncholinergic inhibition of the gastrointestinal tract. Our ability to more accurately define motor abnormalities of the small bowel has been expanded with new diagnostic techniques. There has also been greater delineation of the small bowel motility abnormalities that exist in a number of pathologic conditions. Our therapeutic options have increased as progress in pharmacologic therapy for small bowel dysmotility continues to be advanced.

AB - Tremendous progress continues in the area of small bowel motility and pharmacology. Our understanding of small bowel motility has been further advanced over the past year with studies examining the role of various mediators of gastrointestinal physiology. Additional new evidence supports the role of nitric oxide as a key intracellular messenger for nonadrenergic, noncholinergic inhibition of the gastrointestinal tract. Our ability to more accurately define motor abnormalities of the small bowel has been expanded with new diagnostic techniques. There has also been greater delineation of the small bowel motility abnormalities that exist in a number of pathologic conditions. Our therapeutic options have increased as progress in pharmacologic therapy for small bowel dysmotility continues to be advanced.

UR - http://www.scopus.com/inward/record.url?scp=0027957430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027957430&partnerID=8YFLogxK

U2 - 10.1097/00001574-199403000-00008

DO - 10.1097/00001574-199403000-00008

M3 - Review article

AN - SCOPUS:0027957430

VL - 10

SP - 156

EP - 162

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 2

ER -